Novel non-transgenic method leveraging Cuscuta campestris parasitic vines to deliver targeted microRNAs that induce heritable epigenetic modifications in host crop plants, enabling trait manipulation without genetic engineering.
This research explores a novel, non-transgenic approach to crop trait manipulation using the parasitic plant Cuscuta campestris (dodder). The core discovery is that Cuscuta naturally exports microRNAs into host plants, silencing specific host genes involved in defense signaling, hormone perception, and vascular function. These microRNA-induced gene silencing events trigger pathways associated with DNA methylation, suggesting that Cuscuta can serve as a natural conduit for depositing heritable epigenetic marks at targeted genomic loci in host plants. If validated, this would represent a transgene-free strategy for modifying crop traits, circumventing regulatory, public acceptance, and biosafety challenges associated with transgenic approaches.
Key biological mechanisms:
Potential applications:
This research is at an early-to-mid stage of development. Prior work has established that Cuscuta campestris exports functional microRNAs into host plants and demonstrated silencing of specific host gene targets. The next validation steps involve confirming that DNA methylation marks are deposited at target sites in infested host tissues, then determining whether these marks are maintained and inherited. A longer-term goal is engineering the process to deliver user-designed microRNAs for targeted epigenetic crop modification. The approach is currently at a fundamental research stage (TRL 2–3), with significant validation remaining before agricultural application.
Penn State University is a comprehensive public land‑grant research university with a large multi‑campus footprint across Pennsylvania. Industry engages through a research and technology park adjacent to the flagship campus that houses corporate R&D, co‑located labs, and flexible collaboration space, as well as a statewide extension network that enables field testing, demonstration, and workforce reach. Integration with a major hospital system supports clinical translation, and an applied research laboratory fosters mission‑driven partnerships with government and industry sponsors. Research is supported by competitive federal funding from agencies such as NSF, NIH, DOE, USDA, DoD, and NASA. A dedicated technology transfer office manages IP, licensing, and startup formation to accelerate commercialization.